COVID-19-associated cardiac arrest: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{COVID-19}} | |||
'''For COVID-19 frequently asked inpatient questions, click [[COVID-19 frequently asked inpatient questions|here]]'''<br> | '''For COVID-19 frequently asked inpatient questions, click [[COVID-19 frequently asked inpatient questions|here]]'''<br> | ||
'''For COVID-19 frequently asked outpatient questions, click [[COVID-19 frequently asked outpatient questions|here]]'''<br> | '''For COVID-19 frequently asked outpatient questions, click [[COVID-19 frequently asked outpatient questions|here]]'''<br> | ||
Revision as of 15:30, 8 July 2020
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19-associated cardiac arrest On the Web |
|
American Roentgen Ray Society Images of COVID-19-associated cardiac arrest |
|
Risk calculators and risk factors for COVID-19-associated cardiac arrest |
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayesha Javid, MBBS[2]
Overview
Out-of-hospital cardiac arrest and Sudden Cardiac Death
The sudden cardiac death is defined as the death that occurs within one hour of onset of symptoms in witnessed cases and within 24 hours of last being seen alive when it is unwitnessed. Out-of-hospital cardiac arrest means cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
Pathophysiology
Drug induced
- Since the COVID-19 pandemic, several pharmacological therapies have been proposed, one of them is of two anti-malarial and antirheumatic drugs called Chloroquine or Hydroxychloroquine.
- Due to their cost-effectiveness and easy availability, there is a surge in the use of Chloroquine and Hydroxychloroquine, with or without Azithromycin. The clinical trials in order to estimate their efficacy are still in the preliminary stage, however, a notable concern is of their cardiac adverse effects.
- This includes QT prolongation and Torsade de pointes (TdP) leading to sudden cardiac death.
- The risk is there when these drugs are prescribed separately, however it increases several folds when these drugs are administered together, especially in patients with underlying hepatic disease or renal failure.
Genetic susceptibility:
- Epidemiological studies have shown that African Americans have higher COVID-19 associated morbidity and mortality as compared to people from other ethnic groups.
- Recent studies show that this ethnic predilection is due to the genetic factors which contribute to a common ion channel variant p.Ser1103Tyr-SCN5A which confer an increased risk of drug-induced long QT syndrome (DI-LQTS) and drug-induced sudden cardiac death (DI-SCD).
- p.Ser1103Tyr-SCN5A generates late or persistent sodium current which is further aggravated by hypoxia or respiratory acidosis secondary to lungs involvement in COVID-19.
- This has and has been linked to an increased risk of ventricular arrhythmia (VA) such as torsade de pointes and sudden cardiac death (SCD) in African Americans.
Cytokine storm and heart damage:
Pre-existing heart disease
Epidemiology and Demographics
Incidence
There is a two-times rise in the incidence of Out of hospital Sudden cardiac arrest (OHCA) during the COVID-19 pandemic as compared to the non-pandemic time period.
Mortality
There is a significant increase in the mortality rate of the OHCA patients.[1]
Age
Mean age 69.7 years is observed among patients who experienced Out of hospital Sudden cardiac arrest (OHCA) .[1] .
Gender
Studies show that males have a slightly higher incidence of Out of hospital Sudden cardiac arrest (OHCA) as compared to the females.[1]
Race
A higher incidence is seen among African-Americans as compared to the Caucasians.[2]
Diagnosis
- EKG
- A patient experiencing sudden cardiac death can have ventricular fibrillation associated ECG changes such as ventricular tachycardia with irregular rhythm and indiscernible P waves or QRS complexes.
- Heart block.[3]
- Pulseless electrical activity.[3]
- Other abnormal ECG findings include QT prolongation. ECG shows corrected QT interval (QTc) more than 500 ms..
- Asystole.[3] [4]
Treatment
- Cardiopulmonary resuscitation
- Immediate basic life support or advanced cardiac life support with an automatic external defibrillator is essential to safe the life of the patient. If the COVID-19 infection was confirmed, the EMS personnel is instructed to wear personal protective equipment (PPE) before performing cardiopulmonary resuscitation.
- Implantable Cardioverter Defibrillator (ICD)
- An Implantable cardioverter defibrillator (ICD) is the preferred therapeutic modality in most survivors of sudden cardiac death. This device does not prevent the recurrence of arrhythmia, instead, it terminates them in case if they do recur.
- Pharmacologic therapy in survivors of sudden cardiac arrest
- Antiarrhythmic drugs: Amiodarone is the most effective for preventing recurrent ventricular tachyarrhythmias. It is recommended to immediately give Amiodarone following an event of sudden cardiac arrest in patients with recurrent ventricular tachyarrhythmias as well as for those who have refused Implantable Cardioverter Defibrillator (ICD).
- Beta blocker:It is recommended that almost all patients who survive an episode of sudden cardiac arrest should receive a beta-blocker as part of their therapy in combination with an antiarrhythmic drug, particularly in those patients who have survived sudden cardiac death due to ventricular tachycardia or ventricular fibrillation. Beta-blockers has shown to reduce the future incidence of sudden cardiac death.
Prevention
- Identification and treatment of acute reversible causes of sudden cardiac death.
- Evaluation and management of structural heart disease and arrhythmia.[3]
References
- ↑ 1.0 1.1 1.2 Marijon E, Karam N, Jost D, Perrot D, Frattini B, Derkenne C; et al. (2020). "Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study". Lancet Public Health. doi:10.1016/S2468-2667(20)30117-1. PMC 7255168 Check
|pmc=value (help). PMID 32473113 PMID: 32473113 Check|pmid=value (help). - ↑ Giudicessi JR, Roden DM, Wilde AAM, Ackerman MJ (2020). "Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans". Heart Rhythm. doi:10.1016/j.hrthm.2020.04.045. PMC 7198426 Check
|pmc=value (help). PMID 32380288 PMID: 32380288 Check|pmid=value (help). - ↑ 3.0 3.1 3.2 3.3 Srinivasan NT, Schilling RJ (2018). "Sudden Cardiac Death and Arrhythmias". Arrhythm Electrophysiol Rev. 7 (2): 111–117. doi:10.15420/aer.2018:15:2. PMC 6020177. PMID 29967683 PMID: 29967683 Check
|pmid=value (help). - ↑ Parish DC, Goyal H, Dane FC (2018). "Mechanism of death: there's more to it than sudden cardiac arrest". J Thorac Dis. 10 (5): 3081–3087. doi:10.21037/jtd.2018.04.113. PMC 6006107. PMID 29997977 PMID: 29997977 Check
|pmid=value (help).
[[Category:]]